ERBB2 and breast carcinoma: While patients with a Her2-enriched subtype achieved the greatest benefit from allocation to CEF in this study, premenopausal patients with T3 or node positive breast cancer, and a Her2-enriched subtype obtained no benefit from cyclophosphamide-based chemotherapy as compared to no chemotherapy in the DBCG 77B trial.7 At that time, HER2 targeted therapy was not available for patients with HER2 overexpressing or amplified breast cancers, and with anti-HER2 therapy the effect of anthracyclines on the Her2-enriched subtype might be less clear.